Edition:
United States

Hemispherx Biopharma Inc (HEB.A)

HEB.A on American Stock Exchange

1.26USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$1.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,119
52-wk High
$2.63
52-wk Low
$0.75

HEB.A

Chart for HEB.A

About

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development... (more)
No analyst recommendations are available for HEB.A.

Overall

Beta: 0.44
Market Cap(Mil.): $30.34
Shares Outstanding(Mil.): 24.08
Dividend: --
Yield (%): --

Financials

  HEB.A Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -0.50 -- --
ROI: -47.03 -0.27 13.98
ROE: -47.03 -2.93 14.88

BRIEF-Frigate Ventures reports 6.9 pct passive stake in Hemispherx Biopharma

* Frigate Ventures Lp reports 6.9 pct passive stake in Hemispherx Biopharma Inc as of August 31, 2016 - SEC filing Source text: (http://bit.ly/2cATyOR) Further company coverage:

Sep 07 2016

BRIEF-Sabby Management LLC reports 6.92 pct passive stake in Hemispherx Biopharma

* Sabby Management LLC reports 6.92 percent passive stake in Hemispherx Biopharma Inc as of August 31 - Sec Filing Source text : http://bit.ly/2bFyk25 Further company coverage:

Sep 01 2016

BRIEF-Hemispherx Biopharma announces $5 mln registered direct offering

* Hemispherx Biopharma Inc announces $5 million registered direct offering

Aug 31 2016

BRIEF-Hemispherx Biopharma received approval of its new drug application from ANMAT

* Received approval of its new drug application from anmat for commercial sale of rintatolimod in argentine republic

Aug 26 2016

BRIEF-Hemispherx Biopharma gets approval of NDA to treat chronic fatigue syndrome

* Received approval of NDA in argentine republic for treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome

Aug 23 2016

BRIEF-Hemispherx Biopharma announces 1-for-12 reverse stock split

* Split will reduce number of shares of co's common stock currently outstanding from about 249 million shares to about 20.7 million shares Source text for Eikon: Further company coverage:

Aug 17 2016

BRIEF-Hemispherx says focusing on commercial success by seeking co-development partners

* Hemispherx biopharma announces financial results for the six months ended june 30, 2016

Aug 15 2016

BRIEF-Hemispherx, Avrio strike contract manufacturing deal

* Agreement with Avrio Biopharmaceuticals, Irvine California, to serve as additional contract manufacturer of Hemispherx's Ampligen

Jul 27 2016

BRIEF-Hemispherx outlines key elements of strategic growth plan

* Hemispherx outlines key elements of strategic growth plan and commitment to transparency

Jul 14 2016

BRIEF-Hemispherx updates on status of Alferon manufacturing facility

* Hemispherx updates the status of the Alferon manufacturing facility

Jul 11 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.95 -1.30
Pfizer Inc. (PFE.N) $33.32 --
Merck & Co., Inc. (MRK.N) $61.91 --
GlaxoSmithKline plc (GSK.L) 1,634.00p -13.50
AstraZeneca plc (AZN.L) 4,970.50p -55.50
Baxter International Inc (BAX.N) $46.92 --
MediGene AG (MDG1k.DE) €7.89 -0.23

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.